Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

AAV Genome Titering and Integrity Analysis

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

AAV Genome Titering and Integrity Analysis

CELL & GENE | RNA | BIOLOGICS

Frequently Asked Questions

How does genome titering data impact an IND submission beyond simple concentration values?

Genome titering establishes the precise concentration of AAV genomes (vg/mL), which is fundamental for accurate dosing in IND-enabling toxicology studies. Regulatory bodies require this data as a well-characterized attribute of the therapeutic candidate, directly impacting the interpretation of safety and efficacy data, not only as a quantity metric.

How does AAV genome integrity analysis mitigate risks in preclinical programs?

AAV production can yield a mix of full, empty, and partially-packaged capsids. Integrity analysis identifies the ratio of full-length, transcriptionally-active genomes to these variants. This minimizes clinical risk by ensuring the administered dose is potent and by reducing the load of non-functional particles that could contribute to unwanted immunological responses.

What is the difference between physical titer and functional titer for AAV vectors?

Physical titer (e.g., via ddPCR) quantifies the total number of AAV genomes, while functional titer measures the fraction of those vectors capable of transducing target cells and expressing the transgene. Both are necessary for a comprehensive characterization package that satisfies global regulatory bodies like the FDA and EMA, as they provide complementary data on product quantity and quality.

An accurate determination of vector titer is the foundation of any therapeutic program. It directly informs dosing calculations for preclinical and clinical work, making it a primary analytical metric for characterizing an AAV product. Relying on titer alone, however, provides an incomplete picture of product quality.

A primary challenge is understanding what that titer represents. AAV vector preparations are heterogeneous populations. They contain the desired full-length genetic payload, but also empty capsids and particles containing truncated or incomplete fragments. A high AAV genome titer can be misleading if a significant portion of the capsids are not carrying the functional, full-length payload.

A close-up of a scientist in a lab, wearing blue gloves and examining the results of a gel electrophoresis or Western blot.

Characterizing the Product: Titer and Integrity

Robust analytical methods are required to dissect this heterogeneity. The choice of an analytical platform is tailored to the specific program needs and regulatory phase.

  • Quantitative PCR (qPCR): A standard method for determining the concentration of AAV genomes.

  • Droplet Digital PCR (ddPCR): Provides an absolute quantification of AAV genomes without the need for a standard curve, offering high precision for late-stage preclinical and GxP applications.

  • Analytical Ultracentrifugation (AUC): A biophysical method that can distinguish and quantify full, partial, and empty capsids based on their sedimentation velocity.

Translational Impact of Genome Integrity

Inconsistent or incomplete genetic payload packaging directly impacts the therapeutic hypothesis. Historical nonhuman primate studies have demonstrated significant heterogeneity in AAV genome structures post-transduction (PMID: 20113166), underscoring the need for precise characterization before administration. This molecular variability can affect both the potency and the safety profile of the final product.

The expression of the transgene itself, not just the vector backbone, can influence long-term safety outcomes, making accurate quantification of full, expressible genomes a primary concern (PMID: 16682254). A well-defined integrity profile ensures that data from IND-enabling toxicology studies are based on a consistent and well-understood test article, a requirement for multi-jurisdictional IND and IMPD submissions under ICH guidelines. As one biotech partner noted, Franklin Biolabs provides, “Wonderful services. Excellent team to work with. Vast knowledge in all aspects of vector production and analytics.”

Our analytical platforms provide the resolution needed to build a comprehensive data package for your AAV vector. This approach ensures that every batch is characterized with the scientific rigor required to move forward with confidence. For a deeper look into our AAV program strategy, view our webinar on initiating successful vector projects. The core scientific team responsible for our 100% successful IND rate since 2019, now at Franklin Biolabs since our 2024 launch, applies this same analytical discipline to every program.

These detailed analytics are a core component of our Vector | CMC | Analytics Services, designed to de-risk development and accelerate timelines.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities